Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

RVV Insider Trading (Revive Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$22,896.00
Insider Selling (Last 12 Months): C$0.00

Revive Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Revive Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revive Therapeutics Share Price & Price History

Current Price: C$0.08
Price Change: Price Increase of +0.01 (14.29%)
As of 07/22/2019 09:54 PM ET

This chart shows the closing price history over time for RVV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

Revive Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/30/2021Derrick Alexander WelshDirectorBuy45,000C$0.51C$22,896.002,045,000
See Full Table
America's Lithium Mecca?
Lithium is a precious commodity when it comes to our shift to renewable energy. Developing more domestic sources of the metal has been called a matter of national security, since China hogs 80% of the world's lithium. The U.S. Geological Survey calls one Nevada region the best-known lithium deposit in the world.
Get the Full Story About Nevada Lithium

SEC Filings (Institutional Ownership Changes) for Revive Therapeutics (CVE:RVV)

Revive Therapeutics logo
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.
Read More on Revive Therapeutics

Today's Range

Now: C$0.08
Low: C$0.08
High: C$0.09

50 Day Range

MA: C$0.08
Low: C$0.08
High: C$0.08

52 Week Range

Now: C$0.08
Low: C$0.07
High: C$0.25

Volume

212,852 shs

Average Volume

93,085 shs

Market Capitalization

C$5.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Revive Therapeutics?

Revive Therapeutics' top insider shareholders include:
  1. Derrick Alexander Welsh (Director)
Learn More about top insider investors at Revive Therapeutics.
What Investors Don't Know: Communist China Could Profit Billions From The World "Going Green."
Who controls 80% of the works lithium supply (the most important metal for building EV batteries)? China! And if you're outraged by that fact, then you'll love hearing how this western company is fighting back…
See How This Lithium Play Could Explode